NCGA Submits US-Japan Objectives to USTR

Nov 28, 2018

National Corn Growers Association President Lynn Chrisp yesterday submitted NCGA’s negotiating objectives for a United States-Japan Trade Agreement to the Office of the U.S. Trade Representative. Japan is the second largest market for U.S. corn exports and U.S. corn farmers have been a reliable supplier to this market for more than 50 years.

“Corn farmers have long counted on Japan as a leading export market and have spent decades developing this important partnership,” Chrisp wrote. “NCGA has been advocating for a formal trade agreement with Japan for years and we are pleased to see the Trump administration take this important step, one that we hope will be followed up with other trade agreements in the Asia-Pacific region.”

NCGA’s top priorities for this negotiation are to secure this market access for corn amid intensifying competition from other corn suppliers, to improve market access for other corn co-products, and to address technical, sanitary and phytosanitary, and other non-tariff barriers to trade between the parties, allowing for more efficient trade flows.

To view the full comments, click here.

Source: NCGA

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.